For non-viral gene delivery to be successful, plasmids must move through the cytoplasm to the nucleus in order to be transcribed. While the cytoskeletal meshwork acts as a barrier to plasmid DNA movement in the cytoplasm, the microtubule network is required for directed plasmid trafficking to the nucleus. We have shown previously that plasmid-microtubule interactions require cytoplasmic adapter proteins such as molecular motors, transcription factors (TFs) and importins. However, not all plasmid sequences support these interactions to allow movement to the nucleus. We now demonstrate that microtubule-DNA interactions can show sequence specificity with promoters containing binding sites for cyclic AMP response-element binding protein (CREB), including the cytomegalovirus immediate early promoter (CMV iep ). Plasmids containing CREB-binding sites showed stringent interactions in an in vitro microtubule-binding assay. Using microinjection and real-time particle tracking, we show that the inclusion of TF binding sites within plasmids permits cytoplasmic trafficking of plasmids during gene transfer. We found that CREB-binding sites are bound by CREB in the cytoplasm during transfection, and allow for enhanced rates of movement and subsequent nuclear accumulation. Moreover, small interfering RNA knockdown of CREB prevented this enhanced trafficking. Therefore, TF binding sites within plasmids are necessary for interactions with microtubules and enhance movement to the nucleus.
INTRODUCTION
Non-viral gene therapy has the potential to be a promising therapeutic intervention for various diseases due to its low toxicity and safety concerns. However, to make this a reality, gene transfer efficiency needs to be improved for non-viral vectors. Regardless of the method of gene delivery, the genetic material must move through the cytoplasm to reach the nucleus for gene expression. In order to enhance the movement of these vectors, we must elucidate how plasmid DNA navigates through the cytoplasm to the nucleus and exploit these mechanisms to develop non-viral treatment approaches.
An intact microtubule network and motor proteins such as dynein are necessary for transfected naked DNA and some viruses to traverse the cytoplasm and reach the nucleus. [1] [2] [3] However, the mechanism by which DNA is able to interact with microtubules is unknown. Since DNA does not bind directly to dynein, it is most likely that a multiprotein complex mediates this interaction by bridging both the DNA and dynein. This complex could contain either non-specific or sequence-specific DNA-binding proteins as well as additional proteins that have a role in protein and/or DNA nuclear import, such as importin-b, transportin and RAN. [4] [5] [6] [7] If sequence-specific DNA-binding proteins are involved, only plasmids with these sequences for these DNA-binding proteins would be moved toward the nucleus.
The SV40 enhancer acts as a DNA nuclear targeting sequence (DTS), which binds many NLS (nuclear localization sequence)-containing transcription factors (TFs) to facilitate the entry of plasmids into the nucleus. 8, 9 Whether this enhancer sequence and/or other eukaryotic elements within the plasmid bind the proteins responsible for interactions with dynein for cytoplasmic trafficking is unknown.
In previous studies from our laboratory, we used a microtubule spin-down assay to show in vitro that plasmids could interact with microtubules only in the presence of additional proteins present in cell extract. 2 In these studies, the plasmids that carried both the cytomegalovirus immediate early promoter (CMV iep ) and the SV40 enhancer showed strong interactions with microtubules. Whether either of these specific sequences, or any eukaryotic transcriptional regulatory sequence for that matter, is needed for or have any role in cytoplasmic plasmid trafficking is unknown. However, a large body of data from our laboratory and others demonstrate that many plasmids lacking the CMV promoter are capable of efficient transfection and nuclear import. 8, 9 In the current study, a microtubule spin-down assay was used to determine which, if any, element(s) of the plasmid allow for interactions with microtubules in the presence of cell extract. Plasmids containing binding sites for cyclic AMP response-element binding protein (CREB) showed strong microtubule binding while those lacking CREB-binding sites failed to interact. Although CREB indeed formed complexes with CREB-binding site-containing plasmids within 15 min of electroporation-mediated transfection in living cells, it was not required for movement. Microinjection and realtime particle tracking of labeled plasmids found that plasmids containing CREB-binding sites appear to have faster rates of movement and more rapid nuclear localization than promoter-containing plasmids lacking these sequences. Further, small interfering RNA (siRNA)-mediated knockdown of CREB in cells confirmed that the enhanced movement was indeed due to CREB binding. These results suggest that TFs such as CREB are important components of the plasmid trafficking complex, which mediate DNA movement to the nucleus during gene transfer.
RESULTS

Plasmid interactions with microtubules are sequence-specific in vitro
We have previously shown that plasmids interact with microtubules in the presence of cell extract in an in vitro spin-down assay and use microtubules and associated motors for trafficking to the nucleus. 2, 10 In these experiments, the plasmids used contained the SV40 DTS, the CMV iep , and the GFP or Lux (luciferase gene). Using the microtubule in vitro spin-down assay, a variety of constructs were used to determine which, if any, of these sequence elements were required for microtubule interactions in the presence of cell extract. Using quantitative PCR it was found that pBR322, a plasmid with no eukaryotic sequences, did not fractionate into the pellet, indicating that it was unable to associate with microtubules, whereas pCMVLux-DTS, a plasmid that expresses luciferase from the CMV iep and also contains the SV40 DTS, showed robust binding ( Figure 1a ). When the DTS or the luciferase gene was the only eukaryotic sequence present in the pBR322 plasmid backbone, the plasmids did not associate with microtubules. By contrast, plasmids containing the CMV iep , with or without other eukaryotic elements were found in the pellet fraction, suggesting that it is the CMV promoter that mediates the microtubule-plasmid interaction.
Due to the large number of TFs that bind the SV40 DTS, [11] [12] [13] it was a somewhat surprising observation that the DTS did not also facilitate microtubule interaction. One possibility is that the incubation times were not sufficient to capture all interactions between the plasmid and microtubules. To address this, the plasmid containing only the DTS was incubated with cell extract and microtubules for increasing amounts of time. However, even after 75 min in the presence of an ATP-regenerating system, the DTS-containing plasmid did not associate with microtubules ( Figure 1b) .
CREB-containing promoters mediate microtubule-plasmid interactions
To determine whether other eukaryotic promoters were able to mediate binding of plasmids to microtubules in this assay, a number of different RNA polymerase I and polymerase II promoters were tested for binding (Figure 2a ). While several strong viral, general and cell-specific promoters failed to interact more than did the backbone pBR322 alone, both the CMV iep and CaMV (Cauliflower Mosaic virus) 35S promoter-containing plasmids were able to bind microtubules and pellet following centrifugation. All plasmids varied in size, but there was no correlation between the size of the plasmid and the ability to pellet with the microtubules. These results suggest that there may be a common sequence or sequences shared by these promoters that the others lack that is responsible for microtubule interaction in this assay. Using the TF Search (ver 1.3) (http://www.cbrc.jp/research/ db/TFSEARCH.html) program, the TF consensus binding sites within these promoters were determined using a threshold score of 85.0. The most obvious candidate was CREB: the CMV promoter has 22 binding sites and the CaMV 35S promoter has 9 binding sites for CREB, while none of the other promoters tested contained CREB-binding sites.
To test whether CREB-binding sites were responsible for these interactions, a single CREB-binding site was introduced into pBR322 and was used in the spin-down assay. A single CREB-binding site was sufficient to mediate a plasmid-microtubule interaction (Figure 2b ). Although the interaction is strong, having a single CREB site did not appear to provide interactions as robust as those mediated by the full-length CMV or CaMV promoters, suggesting that the presence of multiple CREB-binding sites within these two promoters provides for even better binding. Alternatively, other TFs that bind to the full-length promoters may provide an additive or a synergistic effect to increase microtubule-plasmid interactions.
CMV promoter binds CREB during gene transfer Although inclusion of CREB-binding sites in the plasmid allowed enhanced interactions with microtubules in the cell-free system, we wanted to know if these plasmid constructs bind CREB in cells. To examine this, several biotinylated plasmid constructs were electroporated into cells. The constructs included plasmids containing or lacking CREB-binding sites in the regulatory sequences (for example, CMV iep or SV40 enhancer, respectively) as well as plasmids carrying either elements or neither. At certain times post-electroporation (15, 30, 60 and 120 min), DNA-protein complexes were cross-linked, cells were lysed, and the biotin-peptide nucleic acid (PNA)-DNA-protein complexes were pulled down using streptavidin-coated beads and analyzed by western blots using antibodies against CREB. As seen in Figure 3 , only those plasmids containing CREB-binding sites (that is, with the CMV iep ) are able to bind this TF at any of the time points. Additionally, CREB bound the plasmids at early times after electroporation, before significant nuclear localization of plasmids occurs. 10 This suggests that this binding occurs during cytoplasmic trafficking, before nuclear entry of DNA.
Plasmids containing the SV40-DTS or CMV promoter traffic in the cytoplasm The apparent CREB dependency seems peculiar since plasmids containing only the SV40 DTS (and no CREB-binding sites) have been shown to allow efficient nuclear import in many cell types, 8, 9, 14 but did not interact with microtubules in the microtubule-binding assay (Figures 1a and b) . Since plasmids require microtubules for movement to the nucleus, these in vitro and in vivo results appear at odds and must be reconciled. Therefore, real-time plasmid tracking was carried out in live cells using different plasmid constructs. Fluorescently labeled plasmids were microinjected into the cytoplasm of A549 cells and cytoplasmic trafficking was monitored via fluorescence microscopy and time-lapse imaging ( Figure 4 ). The same plasmids as in Figure 3 that contain or lack CREB-binding sites were used in these experiments. When pBR322 was injected and followed for up to 1 h after microinjection, most particles failed to show any significant bulk movement and remained largely at the site of injection. Figure 4a shows representative trajectories of three such particles. By contrast, plasmids carrying the CMV iep , the SV40 enhancer, or both sequences showed significant directed movement ( Figure 4a ). When their frequency distribution histograms are plotted, those plasmids containing the CMV iep , SV40 DTS or both show most particles moving at average (net) velocities of around 0.05-0.14 mm s -1 , with individual plasmids moving at rates of up to 0.38 mm s -1 ( Figure 4b ). By contrast, the majority of pBR322 plasmids display rates of o0.05 mm s -1 , which is likely diffusive movement. 15 Additionally, when the net velocities of all tracked plasmids were averaged, the data show that inclusion of the CMV promoter mediates enhanced plasmid velocity compared with those plasmids containing only the SV40 DTS ( Figure 4c ). This enhanced cytoplasmic trafficking may allow for greater movement to the nucleus over a shorter time. This suggests that movement along microtubules is greater for plasmids that contain the CMV promoter and bind CREB during trafficking, and this may explain why only the CREB-binding plasmids pelleted with microtubules in the spin-down assay. To confirm that the plasmids are moving on microtubules, cells were microinjected with labeled plasmids and 20 min later, the cells were fixed and immunofluorescence was used to visualize tubulin ( Figure 4d ). Three-dimensional reconstructions of cells imaged by deconvolution microscopy showed that 478% of the intracellular QD-labeled plasmids colocalized with microtubules with a mean Manders overlap coefficient of 0.85 ± 0.07.
CREB binding is required for the enhanced rate of movement
The particle tracking experiments show that the CMV iep permits enhanced cytoplasmic trafficking over the SV40 DTS enhancer sequence alone following microinjection (Figures 4b and c) . Additionally, DNA-microtubule interactions are strongest for plasmids that contain the CMV promoter (that is, bind CREB) as determined with the spin-down assay (Figures 1 and 2 ). Therefore, net plasmid 43 and all plot areas are mapped to 25Â25 pixel areas. (b) Average cytoplasmic velocity of individual microinjected plasmids. Movement of individual DNA particles, shown in (a), were tracked for up to 10 min using time-lapse imaging (1 frame per second). The average velocity of each was determined using particle tracking software (PolyParticleTracker, MATLAB), and the frequency distribution histograms are plotted as the number of plasmids moving at certain velocities for each construct. At least 50 particles were tracked per construct in three to five separate experiments. (c) Individual microinjected plasmid velocities were averaged for each of the four constructs. Error bars represent mean values+s.d. z Po0.05 compared with pBR-DTS; *Po0.001 compared with pBR322. (d) Colocalization of quantum dot-labeled plasmids with microtubules. Cells were microinjected with biotin-peptide nucleic acid (PNA)-pCMV-DTS plasmids, fixed 20 min post-injection, and labeled with anti-tubulin antibodies and streptavidin-conjugated quantum dots to label plasmids. Cells were imaged using a Â100 objective by deconvolution microscopy and a representative deconvolved Z slice is shown. Scale bar, 10 mm.
velocities were examined when CREB was knocked down in microinjected cells. Using siRNA against CREB, between 66 and 85% knockdown was achieved by 48 h post-transfection (Figure 5a ). At this time, cells were cytoplasmically microinjected with quantum dotlabeled DNA and real-time particle tracking was carried out, as in Figure 4 . The frequency distribution histograms for the four plasmid constructs in the negative control, scramble RNA-transfected cells were very similar to those seen in the untransfected cells (Figure 4b ), indicating that liposome-mediated transfection did not affect the cytoplasmic trafficking of plasmids (Figure 5b ). However, when CREB is knocked down, CMV iep -containing plasmids have histograms that are shifted toward slightly slower velocities, whereas constructs lacking CREB-binding sites (pBR322 and pBR-DTS) have histograms that are relatively unchanged (Figure 5c ). When all plasmid net velocities are plotted together in a scatter plot, the pBR-CMV iep plasmids show an overall shift in velocity toward slower speeds for individual particles when CREB has been knocked down versus when scrambled siRNA was used (Figure 5d ). This shift produced a significantly lower median velocity for pBR-CMV iep plasmids in the knockdown condition compared with the control (Po0.001). Interestingly, the pCMV-DTS plasmids did not show any difference in mean velocity when CREB was knocked down. This is likely due to the presence of multiple binding sites in the SV40 DTS, which bind to TFs other than CREB to mediate microtubule binding and movement. These results indicate that CREB binding to plasmids facilitates the faster movement seen with CMV iep -containing plasmids.
Plasmids displaying greater cytoplasmic velocity also display greater levels of nuclear localization The particle tracking experiments show that CMV promoter-containing plasmids have faster net velocities than those plasmids lacking CREB-binding sites (Figure 4c) . Therefore, one would expect faster nuclear accumulation of nuclear import-competent plasmids containing these sequences. To address this, cells were microinjected with fluorescently labeled plasmids that contain no eukaryotic sequences (pBR322) as a control, or the SV40 DTS alone (pBR-DTS) or both CMV iep and DTS sequences (pCMV-DTS). Cells were subsequently scored for the accumulation of nuclear plasmids at the indicated times. Starting at 60 min post-injection, the CMV iep -containing plasmid localizes to the nuclei of a greater number of cells than does the plasmid carrying the SV40 DTS alone (Figure 6 ). While not demonstrating a direct relationship, these results are consistent with a model in which increased directed movement of plasmids through the cytoplasm may lead to more rapid arrival at the nuclear envelope and greater subsequent levels of nuclear accumulation. 
DISCUSSION
The mechanisms by which plasmid DNA crosses the cytoplasm to the nucleus for successful gene expression are still unknown. However, it is known that motor proteins and an intact microtubule network are required. 1,2 Since non-viral gene therapy and transfections are relatively inefficient, these fundamental cell processes must be elucidated if we are to improve gene delivery and achieve more DNA in the nucleus. In this study, we used a cell-free microtubule-binding assay, plasmid microinjections and real-time particle tracking to examine whether plasmid interaction with microtubules and intracellular trafficking are sequence-specific events. We found that this is the case, and specifically, TF binding sites in the plasmid have an important role in cytoplasmic movement. However, not all TF binding may result in the same efficiency of movement; binding of some factors may allow greater or lesser cytoplasmic trafficking. Moreover, by enhancing plasmid movement through the cytoplasm, they may be more likely to reach the nucleus faster for subsequent import across the nuclear envelope, which could result in decreased cytoplasmic degradation of plasmids and ultimately greater gene transfer efficiency.
The in vitro microtubule spin-down assay suggested that only those plasmids containing CREB-binding sites are able to interact with microtubules ( Figure 2 ). However, this is a cell-free system and may only show the strongest interactions. We know from previous work that plasmids containing the SV40 DTS, which does not bind CREB, are able to traverse the cytoplasm to the nucleus, 8, 9 and this requires interaction with microtubules. 1,2 Therefore, there is a discrepancy between what we have seen in vivo and in vitro. Several possibilities could account for this: first, the in vitro assay may be highly stringent and only detect the strongest interactions; second, conditions of the assay were such that not all interactions were allowed to form (for example, not enough time for binding, or non-optimized buffers and protein concentrations); or third, the in vitro assay does not reflect what actually happens in cells. All of our results, including the presence of CREB in precipitated plasmid complexes during transfection and its ability to enhance, but not be required for, plasmid trafficking in cells, suggests that the first possibility is most likely.
In the DNA precipitation experiments, the TF CREB bound to plasmids containing the CMV promoter during early time points and likely links the plasmids to microtubules (Figure 3 ). Because DNA is located in the cell nucleus, and it is where TFs function, it is not obvious to think about TF binding to DNA as something that occurs in the cytoplasm. However, like all proteins, TFs are translated in the cytoplasm and are regulated via cytoplasmic sequestration until activation, upon which the protein translocates to the nucleus. 16 Although CREB is activated by phosphorylation and acts in concert with p300 and CBP in the nucleus, even bacterially produced CREB, which is unphosphorylated (similar in this respect to classic cytoplasmic CREB), is able to bind to its consensus sequence on DNA, 17, 18 suggesting that cytoplasmic CREB may indeed be capable of binding to DNA. Our experiments show that this is the case. This is, to our knowledge, the first demonstration of TF binding to plasmids during transfection.
It has been shown that plasmids begin to localize to the nucleus within 30-45 min following cytoplasmic microinjection. 10 The fact that CREB can be pulled down as part of the plasmid complex within 15 min of electroporation-mediated introduction into the cell suggests that this factor binds to the DNA while it is still in the cytoplasm, before nuclear entry. While a number of other reports have shown either that inclusion of TF binding sites to plasmids can increase nuclear localization 1, 6, [19] [20] [21] [22] [23] or that knockdown of specific TFs or use of dominant negatives can inhibit nuclear localization of the plasmids, 1, 20 none have shown that the factors do indeed bind to the DNA in cells during the transfection process. Further, that knockdown of CREB reduces cytoplasmic movement of the plasmids suggests it binds and has a functional role in cytoplasmic trafficking. However, the fact that plasmids containing only the SV40 DTS, which lacks CREB-binding sites but has binding sites for a number of other TFs, are able to effectively move following microinjection suggests that CREB is not solely responsible for this plasmid movement. Indeed, there are a number of other cytoplasmic proteins that likely mediate intracellular movement as components of the 'trafficking complex' , such as importin-b, RAN, transportin, dynein and TFs other than CREB (Figure 7) . 6, 7, 22 What roles each of these have in cytoplasmic trafficking remains to be seen.
It is interesting in the CREB pull-down experiments that the plasmid carrying only the CMV iep forms CREB-DNA complexes that can be pulled down at relatively equal abundance at all times up to 2 h after transfection. By contrast, the plasmid carrying both the CMV iep and the SV40 DTS forms complexes within 15 min of transfection but by 60 min, very little CREB is pulled down with the plasmid and by 2 h, no CREB remains complexed with the DNA. Since the latter plasmid carries the SV40 DTS and can be transported into the nucleus by 60 min, while pBR-CMV does not support nuclear import, 9 it is possible that different plasmid-protein complexes exist in the cytoplasm and the nucleus or that the complexes are dynamic. This is likely, since it has been shown that TF localization and interactions with DNA in the nucleus can be transient or form highly stable protein aggregates. 24, 25 Perhaps plasmid-bound TFs such a CREB redistribute to areas of higher affinity so that they move off the plasmids and onto genomic DNA. Alternatively, the nuclei of transfected cells may not have been effectively lysed, leaving the nuclear fractions of CREB in the membranous pellet following centrifugation of lysates. This would explain why plasmids containing Figure 7 Possible protein interactions in the plasmid trafficking complex. Our model of plasmid interaction with microtubules is not a direct one, and involves transcription factor binding to unique sequences on the plasmid (that is, CREB binding to CMV iep ). One or more of the transcription factor NLSs are bound by importins, which are bound by the motor protein dynein and can move along microtubules toward the nucleus for import. Other adaptor molecules, such as chaperones, MAPs (microtubule-associated proteins), and nuclear import proteins may be part of this larger complex as well. MT, microtubule.
the SV40 DTS, which localizes to the nucleus in about an hour, do not show CREB binding at the later time points.
Inclusion of the CMV iep , which was shown to bind CREB as early as 15 min post-transfection, enabled plasmids to move faster compared with plasmids that lack the sequence. The SV40 DTS allowed significantly increased cytoplasmic velocity compared with the pBR322 plasmid, showing that this sequence alone is sufficient for plasmid movement during gene transfer (Figure 4) . However, CREBbinding plasmids have greater trafficking, which is highly favorable in gene transfer where the plasmid DNA needs to rapidly reach the nucleus. In fact, if unable to successfully move through the cytoplasm, much of the internalized DNA may be degraded by nucleases present in the cytoplasm within several hours. 26, 27 When plasmids either containing or lacking CREB-binding sites were compared for their ability to accumulate in nuclei over longer time intervals, there was a higher percentage of cells with nuclear plasmid from 1 to 4 h postinjection when the plasmid carried the CMV iep and SV40 DTS compared with the DTS sequence alone (Figure 6 ). This observation is important, since the plasmid tracking experiments only analyze movement over short periods of time (5-10 min), and may not reflect bulk plasmid movement that is directed toward the nucleus over longer time intervals.
The difference in average DNA velocity between those plasmids containing the CMV promoter and lacking it may be attributable to the affinity of the bound TFs for microtubule motors. For example, if CREB binds more efficiently or tightly to microtubule motors than do other TFs, this would allow the bound cargo (that is, plasmids) to also have enhanced trafficking. Indeed, it has been shown that many cargoes including virus particles and organelles bind multiple motor proteins and that the number of bound motors may be proportional to the rates of movement and processivity. 28 Further, the multiple CREB-binding sites within the CMV iep could enable more motors to bind to the plasmid, thereby accounting for the enhanced movement observed. Alternatively, CREB may interact with higher-order regulatory factors that regulate directed microtubule-mediated trafficking, such as dynactin or microtubule-associated proteins. 29, 30 The rates of movement for the plasmid constructs containing promoter or enhancer sequences (0.05-0.4 mm s -1 ) are consistent with those measured for various components in the cytoplasm that also move on microtubule-associated motor proteins. For example, the motors kinesin and dynein are reported to move at similar average rates of around 0.5-1.5 mm s -1 . [29] [30] [31] Organelles such as peroxisomes are moved via motors around the cytoplasm at rates of 0.1-0.3 mm s -1 , 32 but the rates vary depending on cell types. Viral particles such as adenovirus and herpes simplex virus have been recorded moving at rates of about 0.5 mm s -1 in cells, [33] [34] [35] which is similar to vesicular movement in neuritis, 36 suggesting that endocytosed or lipid encapsulated particles may move at similar rates. In one study of liposomemediated transfection, it was observed that microtubule-associated lipoplexes moved with an average velocity of just 0.02 mm s -1 , a rate much slower than that seen for motor protein-mediated movement, suggesting that this movement may have been more restricted and diffusive in nature. 37 In this study, we have shown that plasmid-microtubule interactions are sequence specific, much like plasmid DNA nuclear import. 8 While specific binding of TFs such as DNA-microtubule interactions CREB may enhance this movement, binding of a number of other TFs, including nuclear factor-kB, are likely needed for movement. Moreover, these studies show that increasing the rates of movement through the cytoplasm results in greater accumulation of importcompetent plasmids in the nucleus, and therefore greater gene expression. By determining the various protein adaptors required for DNA cytoplasmic trafficking and nuclear import, we can further explore ways to modulate and enhance transfection and gene therapy.
MATERIALS AND METHODS
Plasmids, PNA and quantum dot labeling
Plasmids pBR322, pBR-RSV, pBR-CMV and pBR-DTS are based on the pBR322 backbone and carry no eukaryotic sequences, the Rouse Sarcoma Virus Long Terminal Repeat promoter, the CMV immediate early promoter/ enhancer and the SV40 DTS, respectively. 9 Plasmids pCMV-Lux-DTS and pCMV-Lux express the luciferase gene from the CMV immediate early promoter/enhancer and contain or lack the SV40 DTS. 9 Plasmid pTA-flk-1, and pTA-endothelin are TA cloning vectors (Invitrogen, Carlsbad, CA, USA) that carry the flk-1 promoter (À285 to +268) or the endothelin promoter (À204 to +4). 38 The 35S promoter from CaMV is carried on the plasmid pUC8-35S, which was a generous gift from Cathy Radenbaugh (Colorado Sate University). 39 The human a-integrin promoter 40 (1100 bp, À505 to +455) was PCR amplified from human genomic DNA and cloned into the TA cloning vector (Invitrogen). The human type I a 2 procollagen (hCol1a2) promoter (-267 to +45) was PCR amplified from human genomic DNA and was subcloned into the pGL3 vector from Promega (Madison, WI, USA). The plasmid pHr-BES contains the human polymerase I (pol I) promoter and the first 700 bp of the transcribed 45S pre-ribosomal RNA (rRNA) sequence inserted into a pBR322 backbone. 41 Plasmid pUB6/V5-His/LacZ carries the Ubiquitin C promoter (Invitrogen). The CREB plasmid was created using the TOPO cloning kit (Invitrogen) by inserting the CREB-binding site (5¢-TGACG TCAAGATCTA-3¢), using the annealed primers (5¢-TGACGTCAAGATCTA-3¢) and (3¢-AACTGCAGTTCTAGA-5¢), into the multiple cloning site. All plasmids were purified from Escherichia coli using Qiagen Gigaprep kits as described by the manufacturer (Qiagen, Chatsworth, CA, USA). Plasmids used in the CREB pull-down and microinjection experiments contain the GeneGrip1 PNAbinding site (Gene Therapy Systems, San Diego, CA, USA). Briefly, plasmids were labeled with biotinylated PNA in Tris EDTA buffer at 37 1C for 2h, followed by isopropanol precipitation to remove unbound biotin-PNA. Microinjected plasmids were labeled with fluorescent quantum dots (Qdot 605; Invitrogen) by incubating the streptavidin-conjugated nanocrystals with biotinlabeled plasmids (0.5 mg ml -1 ) at 371C for 1 h followed by washing in 0.5Â phosphate-buffered saline three times, then filtering through Microsep 1000 K filters (Pall Life Sciences, Ann Arbor, MI, USA) to remove unbound quantum dots.
Cell culture, electroporation and siRNA transfections
Human adenocarcinoma A549 cells (#CCL-185; American Type Culture Collection, Rockville, MD, USA) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1Â antimycotic/ antibiotic solution (Invitrogen).
For electroporations, cells were grown to confluency in six-well dishes, and rinsed twice with 1Â phosphate-buffered saline. Ten micrograms of plasmid in 750 ml of phosphate-buffered saline was added to each well, and one 165 mV square wave electric pulse was applied for 35 ms using a PetriPulser electrode (BTX, San Diego, CA, USA).
For siRNA transfections, cells were grown in six-well dishes and washed twice with phosphate-buffered saline. Each well received 50 nM siRNA against CREB (CAUUAGCCCAGGUAUCUAUtt, ID#s4389, lot ASO0JJZ9) or scramble control (Negative control #1, lot ASO0J3TO) (Ambion Inc., Austin, TX, USA) in Transfection Medium (Santa Cruz, Santa Cruz, CA, USA), and cells were transfected according to the manufacturer's instructions. Two days after transfection, cells were first microinjected for analysis of DNA trafficking, then lysed in Promega lysis buffer (Promega). Lysates were boiled for 5 min in Laemmli sample buffer, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and proteins were transferred to nitrocellulose membranes and anti-CREB antibodies (1:200, ab31387; Abcam, Cambridge, MA, USA) were used to probe the membrane. Chemiluminescence detection was used to determine CREB knockdown with siRNA. CREB knockdown was determined relative to actin levels by stripping the nitrocellulose membrane and re-probing with anti-actin antibodies (1:1000, #C5838; Sigma-Aldrich, St Louis, MO, USA).
Microinjections and particle tracking
For microinjections, A549 cells were grown on coverslips in Mattek dishes (Ashland, MA, USA), and Hoechst 33242 nuclear stain (Invitrogen) was added to the medium before injections. For siRNA experiments, microinjections were done 2 days after transfection. Cells were cytoplasmically microinjected with quantum dot-labeled plasmid constructs (0.5 mg ml -1 ) using an Eppendorf Femtojet system (Hauppauge, NY, USA) as previously described. 42 Immediately after injections, fluorescent plasmids were imaged in the cytoplasm using a Leica DMI 6000 B inverted microscope (Allendale, NJ, USA) with a Â100 objective (N.A. 1.47) and a Hamamatsu EM-CCD camera (Hamamatsu, Japan). Series of images were collected at 1 frame per second for 5-10 min using Volocity software (Improvision, Waltham, PA, USA). This was repeated for different fields of injected cells for up to 1 h after injection. The collected series of images were converted to movie files using ImageJ (http://imagej.nih.gov/ij/), and a modified algorithm written in MATLAB (PolyParticleTracker) was used to track DNA particles and create representative particle trajectories. 43 Briefly, after choosing the region of interest in the images with fluorescent plasmids, particles were fitted to a fourth order polynomial weighted by a two-dimensional Gaussian distribution. The center of the particle was used as the maximum point in the fit. The average velocity of individual tracked particles was determined for 35-50 plasmids per condition, using a minimum of 20 frames in focus as a cutoff.
For the nuclear localization experiments, cells were microinjected with CY3-PNA-labeled plasmids (pBR322, pBR-DTS and pCMV-DTS at 0.5 mg ml -1 ) and imaged as described above. Culture dishes were placed in a 37 1C, 5% CO 2 incubator for 30, 60, 90, 120 or 240 min and then cells were viewed and imaged to determine the number of injected cells that had plasmids in the nucleus at each time point. Typically, 100 cells were injected for each plasmid and time point and the experiment was repeated a minimum of three times.
Immunofluorescence A549 cells were grown on coverslips and microinjected as above with PNAbiotin-labeled plasmids (pCMV-DTS) and then incubated for 20 min at 37 1C. Cells were fixed for 10 min in 100% ice-cold methanol, coverslips were washed with 1Â phosphate-buffered saline and immunofluorescence was carried out using primary antibodies against b-tubulin (1:1000; Sigma-Aldrich Corp.) and secondary Alexa 488 antibodies (1:200; Invitrogen) to stain microtubules. Injected biotinylated plasmids were labeled with fluorescent quantum dots post-cell-fixation (30 nM Qdot 605; Invitrogen) by incubating the coverslips with streptavidin-conjugated nanocrystals for 1 h at room temperature followed by washing with 1Â phosphate-buffered saline. The coverslips were then mounted onto glass slides using Qmount Qdot mounting medium (Invitrogen). Multiple z-series of cells were acquired using a Leica DMI 6000 B inverted microscope with a Â100 objective (N.A. 1.47) and a Hamamatsu EM-CCD camera. Volocity software iterative restoration deconvolution (Perkin-Elmer, Waltham, MA, USA) was used on the resulting images and colocalization quantified on the three-dimensional reconstructions by determining the mean Manders overlap coefficient of 13 different cells with over 100 particles.
Microtubule spin-down assay
Purified bovine brain tubulin, 5 mg ml -1 (Cytoskeleton Inc., Denver, CO, USA) was placed on ice and 2.5 ml of general tubulin buffer (80 mM PIPES (1,4-piperazinediethanesulfonic acid) pH 7.0, 1 mM MgCl 2 , 1 mM EGTA and 50% glycerol) was added. The tubulin was allowed to polymerize for 20 min at 35 1C and then stabilized by the addition of 20 mM taxol (Cytoskeleton Inc.). Tubulin (10 mg) was incubated with DNA (20 ng) and/or cell extract (24 mg) in general tubulin buffer containing 20 mM taxol for 30 min, placed over cushion buffer (general tubulin buffer with 50% volume/volume glycerol and 20 mM taxol) and centrifuged at 100 000 g for 40 min in an Airfuge (Beckman Instruments Inc., Palo Alto, CA, USA). The pellet was re-suspended in cushion buffer for PCR. Cell extract was prepared as described. 44 
Real-time quantitative PCR
Quantitative, real-time PCR was performed in a 20-ml reaction volume, using the DyNAmoTM SYBRR Green qPCR Kit as described by the manufacturer (Finnzymes, Espoo, Finland). Reactions were carried out and quantified with the MJ Research Opticon 2. The supernatants and pellets from the microtubule spin-down assays were diluted 1:1 in water and 4 ml were used for the reactions. All samples were run in duplicate. The primers amplified a 116-bp region of the b-lactamase gene present in the plasmids. Standard curves were generated using seven 10-fold dilutions of pCMV-Lux-DTS, and the threshold was set manually by determining the best-fit line for the quantitation of the standards. A melting curve analysis was performed to ensure reaction specificity. The amount of plasmid present in supernatant and pellet of each sample was determined based on the standard curve. The percentage of DNA present in the pellet was determined by quantifying the amount of DNA in the pellet compared with the total DNA present in the combined supernatant and pellet fractions of each sample. All experiments were preformed at least three times.
Live cell plasmid pull downs
Biotinylated plasmid DNA constructs (pBR322, pBR-CMV, pBR-DTS and pCMV-DTS) were electroporated into adherent cells, and at desired times post-electroporation, plasmid DNA-protein complexes were cross-linked with formaldehyde, cells were lysed, and the resulting biotin-plasmid-protein complexes were pulled down as previously described. 6 Resulting lysate proteins were run in sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Crude lysates were run as a positive control on each gel. The membranes were probed with anti-CREB antibodies (1:200; Abcam), and chemiluminescence detection was used to determine levels of bound CREB. All experiments were performed in duplicate wells and repeated at least four times.
